SARS-CoV-2 correlates of protection in a Latino-origin population

Document text

Principal Investigator: Marcos  Lopez
Organization: UNIVERSITY OF PUERTO RICO MED SCIENCES
Fiscal Year: 2022
Award: $407,099
Funding agency: National Cancer Institute

The rapid global spread of SARS-CoV-2 has had a significant impact on the cancer population. SARSCoV-2 infection of hematopoietic stem cell transplant (HSCT) recipients leads to a poor prognosis with a ~68% survival rate. Immune mediated protection is critical to protect the HSCT population. However, there are significant gaps in our understanding of vaccine induced immune responses in the HSCT patient population. This proposed research will greatly advance our understanding of 1) mRNA vaccine driven immune responses in immune compromised subject populations, and 2) the functionality of the SARS-CoV-2 antigen specific T and B cell response in the HSCT population; 3) the role of the adaptive immune response in controlling breakthrough infections. The results of this proposal will have both short and long-term impacts. In the short term we will define a series of critical parameters that could improve the quality of life of HSCT patients during the pandemic. These studies will define the immunogenicity of mRNA SARS-CoV-2 vaccines before and after boosters. In two cohorts we will surveil for asymptomatic and symptomatic SARS-CoV-2 infections and evaluate the level of vaccine immunity close to the time of the breakthrough infection. In the long-term the SARS-CoV-2 pandemic was the 3rd global transmission of a novel coronavirus in the past 20 years. It is likely that there will be outbreaks in the future with currently unknown coronaviruses, and thus it is critical to determine now how high-risk groups respond to vaccination and if they require frequent booster vaccinations or potentially higher vaccine doses. Given the speed and efficacy of the mRNA vaccine platform, it is highly likely that the use of this vaccine platform will be expanded to combat other known pathogens, but also could be used to combat any range of potential emerging viral pathogens. The strength, breadth, and durability of responses to mRNA vaccines needs to be determined in different risk groups in longitudinal cohorts now, in order to prepare for future epidemics/pandemics.

Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><Active Follow-up><African><Antibodies><Antibody titer measurement><Assay><Automobile Driving><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><Black American><Blood Circulation><Bloodstream><Booster Immunization><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 antibody><COVID-19 antigen><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 predisposition><COVID-19 public health crisis><COVID-19 severity><COVID-19 susceptibility><COVID-19 test><COVID-19 tests><COVID-19 vaccine><COVID-19 virus><COVID-19 vulnerability><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 severity><COVID19 test><COVID19 tests><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancers><Causality><Circulation><Clinical><CoV emergence><CoV-2><CoV2><Collaborations><Communicable Diseases><Coronaviridae><Coronavirus><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Dengue><Detection><Development><Disease Outbreaks><Disease Outcome><Dissection><Dose><Drugs><ELISA><Enzyme-Linked Immunosorbent Assay><Eperythrozoon><Epidemic><Epidemiology><Etiology><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Future><Genetic><Grippe><HSC transplantation><Haemobartonella><Health Care Systems><Health Policy><Healthcare Systems><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hispanic Populations><Hispanic group><Hispanic individual><Hispanic people><Hispanics><Host Factor><Host Factor Protein><IRB><IRBs><IgA><IgG><IgM><Immune><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunoglobulin A><Immunoglobulin G><Immunoglobulin M><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Institutional Review Boards><Integration Host Factors><Investigators><Island><Knowledge><Laboratories><Latin American><Latino><Latino Population><Latino group><Latino individual><Latino people><Latinos><Long-term cohort><Longitudinal cohort><Longterm cohort><Malignant Neoplasms><Malignant Tumor><Mediating><Medication><Messenger RNA><Methods><Mycoplasma><Outbreaks><Outcome><Patients><Pattern><Pharmaceutic Preparations><Pharmaceutical Preparations><Phenotype><Population><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Predisposition><Prevalence><Privatization><Prognosis><Protocol><Protocols documentation><Public Health><Puerto Rican><Puerto Rico><QOL><Quality of life><RNA vaccine><RNA-based vaccine><Research><Research Personnel><Researchers><Respiratory syncytial virus><Risk><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 antigen><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 predisposition><SARS-CoV-2 severity><SARS-CoV-2 susceptibility><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV-2 vaccine><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Science><Secondary Immunization><Series><Serodiagnoses><Serological Diagnosis><Serology><Seroprevalences><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Severities><Source><Speech><Speed><Survival Rate><Susceptibility><T-Cells><T-Lymphocyte><Technology><Testing><Time><Transmission><Transplant Recipients><Trust><Uncertainty><Vaccination><Vaccines><Virus><Washington><World Health Organization><Wuhan coronavirus><ZIKA><active followup><adaptive immune response><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antigen-specific T cells><biobank><biorepository><booster vaccination><breakthrough infection><causation><chikungunya><clinical diagnostics><cohort><combat><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><cytokine><depository><developmental><diagnostic platform><diagnostic serology><diagnostic system><disease causation><disparities in race><doubt><driving><drug/agent><emergency use authorization><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><enzyme linked immunoassay><epidemiologic><epidemiological><follow up><follow-up><followed up><followup><hCoV19><health care policy><healthcare policy><high risk group><high risk population><host response><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interest><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA><mRNA vaccine><mRNA-based vaccine><malignancy><medical diagnostic><nCoV><nCoV2><neoplasm/cancer><new CoV><new corona virus><new coronavirus><news><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><pathogen><pathogenic virus><patient population><predisposed to Coronavirus disease 2019><programs><race disparity><racial disparity><racial inequality><racial inequity><racially unequal><recruit><repository><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social group><social role><social vulnerability><socio-economic><socio-economically><socioeconomically><socioeconomics><study population><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><thymus derived lymphocyte><transmission process><transplant patient><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine platform><viral pathogen><virus pathogen><volunteer>